Metamizole for Postoperative Pain Therapy in Infants Younger than 1 Year

Abstract

Background Due to possible serious adverse drug reactions (ADRs), the use of metamizole for postoperative pain therapy in infants is a subject of debate. Safety studies with large sample sizes are missing.

Aim This prospective multicenter observational study was conducted to evaluate the use of metamizole in infants younger than 1 year undergoing surgery with a particular focus on possible serious ADRs (e.g., hemodynamic, anaphylactic or respiratory reactions, and agranulocytosis).

Methods Infants aged up to 1 year (American Society of Anesthesiologists [ASA] I–III) receiving a single dose of metamizole for postoperative pain therapy were enrolled. Patient demographics, main and secondary diagnosis, surgical procedures performed, metamizole dose, hemodynamic data, use of other analgesics and regional blocks, results of pain measurement, and incidence of ADRs were documented using a standardized case report form.

Results A total of 316 infants observed at five pediatric centers were included for analysis (age 4.4 ± 3.7 [0.06–12] months). Mean metamizole dose was 17.8 ± 3.1 (9.2–29.8) mg·kg⁻¹. Mean arterial pressure (MAP) remained stable during metamizole infusion (MAP before infusion 45 ± 9.5 [25–95] and after infusion 45 ± 9.2 [25–99] mm Hg). Erythema was observed in one patient (ADRs total: 0.3%, 95% confidence interval: 0.27–0.32). No respiratory adverse events directly related to the metamizole administration and no clinical signs of agranulocytosis were reported.

Conclusion Single intravenous doses of metamizole used for prevention or treatment of postoperative pain were safe in more than 300 infants younger than 1 year. The statistical probability of serious ADRs (e.g., hemodynamic, anaphylactic or respiratory reactions) was lower than 1%. The sample size and follow-up were not sufficient to detect agranulocytosis.

Keywords

metamizole - dipyrone - infants - postoperative pain therapy - adverse drug reactions

• References

• 1 Hoffmann F, Meinecke P, Freitag MH, Glaeske G, Schulze J, Schmiemann G. Who gets dipyrone (metamizole) in Germany? Prescribing by age, sex and region. J Clin Pharm Ther 2015; 40 (03) 285-288
• 2 Stammschulte T, Ludwig WD, Mühlbauer B, Bronder E, Gundert-Remy U. Metamizole (dipyrone)-associated agranulocytosis. An analysis of German spontaneous reports 1990-2012. Eur J Clin Pharmacol 2015; 71 (09) 1129-1138
• 3 Fieler M, Eich C, Becke K. , et al. Metamizole for postoperative pain therapy in 1177 children: A prospective, multicentre, observational, postauthorisation safety study. Eur J Anaesthesiol 2015; 32 (12) 839-843
• 4 Büttner W, Finke W, Hilleke M, Reckert S, Vsianska L, Brambrink A. [Development of an observational scale for assessment of postoperative pain in infants]. Anasthesiol Intensivmed Notfallmed Schmerzther 1998; 33 (06) 353-361
• 5 Curtis BR. Drug-induced immune neutropenia/agranulocytosis. Immunohematology 2014; 30 (02) 95-101
• 6 Blaser LS, Tramonti A, Egger P, Haschke M, Krähenbühl S, Rätz Bravo AE. Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports. Eur J Clin Pharmacol 2015; 71 (02) 209-217
• 7 Huber M, Andersohn F, Sarganas G. , et al. Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study. Eur J Clin Pharmacol 2015; 71 (02) 219-227
• 8 Basak GW, Drozd-Sokołowska J, Wiktor-Jedrzejczak W. Update on the incidence of metamizole sodium-induced blood dyscrasias in Poland. J Int Med Res 2010; 38 (04) 1374-1380
• 9 Engel RR, Grohmann R, Rüther E, Hippius H. Research methods in drug surveillance. Pharmacopsychiatry 2004; 37 (Suppl. 01) S12-S15
• 10 Işık M, Kaya Z, Belen FB, Aktaş AT, Tezer H, Gürsel T. Life-threatening agranulocytosis, anemia, and plasmacytosis after dipyrone use for fever in a child. J Pediatr Hematol Oncol 2014; 36 (01) e46-e48
• 11 Tavil B, Cetin M, Gumruk F, Ayvaz D, Cengiz AB. Metamizole-induced bicytopenia reversed by G-CSF and IVIG treatment in a child. Pediatr Hematol Oncol 2014; 31 (02) 117-119
• 12 Meyer O, Gaedicke G, Salama A. Demonstration of drug-dependent antibodies in two patients with neutrophenia and successful treatment with granulocyte-colony-stimulating factor. Transfusion 1999; 39 (05) 527-530
• 13 Macías E, Ruiz A, Moreno E, Laffond E, Dávila I, Lorente F. Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to metamizol. Allergy 2007; 62 (12) 1462-1464
• 14 Bajoghli M, Ajudani TS, Gharavi M. Generalized oedema of newborn associated with the administration of dipyrone. Eur J Pediatr 1977; 126 (04) 271-274
• 15 Rollason V, Desmeules JA. Use of metamizole in children and the risk of agranulocytosis: is the benefit worth the risk?. Eur J Anaesthesiol 2015; 32 (12) 837-838
• 16 Kötter T, da Costa BR, Fässler M. , et al. Metamizole-associated adverse events: a systematic review and meta-analysis. PLoS ONE 2015; 10 (04) e0122918
• 17 Messerer B, Grögl G, Stromer W, Jaksch W. [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management]. Schmerz 2014; 28 (01) 43-64
• 18 Pogatzki-Zahn E, Chandrasena C, Schug SA. Nonopioid analgesics for postoperative pain management. Curr Opin Anaesthesiol 2014; 27 (05) 513-519
• 19 Koster HT, Avis HJ, Stevens MF, Hollmann MW. [Metamizole in postoperative pain management]. Ned Tijdschr Geneeskd 2012; 156 (14) A4323
• 20 Rakow H, Finke W, Mutze K. Recommendations for perioperative pain therapy in children. Anästh Intensivmed 2007; 48: S99-S103